Osteoporosis screening, HRT "reasonably cost-effective," OTA says.
This article was originally published in The Gray Sheet
Executive SummaryOSTEOPOROSIS SCREENING, HORMONE REPLACEMENT THERAPY "REASONABLY COST-EFFECTIVE" as prophylaxis against hip fracture and heart disease, an Aug. 29 Office of Technology Assessment background paper maintains. Entitled "Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy," the background paper was requested by the Senate Special Committee on Aging and the House Select Committee on Aging. The analysis looks at several osteoporosis treatment options, focusing primarily on two regimens that call for either bone mineral density screening coupled with targeted HRT or, alternatively, HRT for all post-menopausal women.
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.